# US 2026/0062475 A1 · Il13 and il31 bispecific polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062475 A1
- Document ID: US20260062475A1
- Status: Published application
- Kind: A1
- Application number: 19/316,633
- Filed: 2025-09-02
- Published: 2026-03-05
- Earliest claimed: 2024-09-03
- Assignees: Attovia Therapeutics, Inc.
- Applicants: Attovia Therapeutics, Inc.
- Inventors: Jin Wook CHOI; Lam NGUYEN; Jing ZHANG; Shyr Jiann LI; David BELLOVIN; Ole Petter VEIBY; Hangjun ZHAN; Lequn ZHAO
- Web page: https://patentgrep.com/patent/US20260062475A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 17/04: Antipruritics
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are bispecific polypeptides that bind IL13 and IL31 and methods of using IL13 and IL31 bispecific polypeptides to modulate the biological activity of IL13 and/or IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL13 and IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL13-associated condition and/or an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

## Claims

### Claim 1

A bispecific polypeptide that binds IL31 and IL13, wherein the polypeptide comprises:
i) a first co-binder that specifically binds IL31 comprising a first Variable Heavy domain of Heavy chain 1 (VHH1) and a second VHH (VHH2), and ii) a second co-binder that specifically binds IL13 comprising a third VHH (VHH3) and a fourth VHH (VHH4), wherein:
a) the VHH1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:5; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:7; the VHH2 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:16; a CDR2 comprising the amino acid sequence of SEQ ID NO:17; and a CDR3 comprising the amino acid sequence of SEQ ID NO:18; the VHH3 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:31; a CDR2 comprising the amino acid sequence of SEQ ID NO:32; and a CDR3 comprising the amino acid sequence of SEQ ID NO:33 or 60; and the VHH4 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:42; a CDR2 comprising the amino acid sequence of SEQ ID NO:43; and a CDR3 comprising the amino acid sequence of SEQ ID NO:44 or 63; or
b) the VHH1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:5; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:7; the VHH2 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:16; a CDR2 comprising the amino acid sequence of SEQ ID NO:17; and a CDR3 comprising the amino acid sequence of SEQ ID NO:18; the VHH3 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:31; a CDR2 comprising the amino acid sequence of SEQ ID NO:32; and a CDR3 comprising the amino acid sequence of SEQ ID NO:60; and the VHH4 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:42; a CDR2 comprising the amino acid sequence of SEQ ID NO:43; and a CDR3 comprising the amino acid sequence of SEQ ID NO:63; or
c) the VHH1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:9; and a CDR3 comprising the amino acid sequence of SEQ ID NO:10; the VHH2 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:19; a CDR2 comprising the amino acid sequence of SEQ ID NO:20; and a CDR3 comprising the amino acid sequence of SEQ ID NO:21; the VHH3 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:34; a CDR2 comprising the amino acid sequence of SEQ ID NO:35; and a CDR3 comprising the amino acid sequence of SEQ ID NO:36 or 61; and the VHH4 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:45; a CDR2 comprising the amino acid sequence of SEQ ID NO:46; and a CDR3 comprising the amino acid sequence of SEQ ID NO:47 or 64; or
d) the VHH1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:9; and a CDR3 comprising the amino acid sequence of SEQ ID NO:10; the VHH2 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:19; a CDR2 comprising the amino acid sequence of SEQ ID NO:20; and a CDR3 comprising the amino acid sequence of SEQ ID NO:21; the VHH3 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:34; a CDR2 comprising the amino acid sequence of SEQ ID NO:35; and a CDR3 comprising the amino acid sequence of SEQ ID NO:61; and the VHH4 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:45; a CDR2 comprising the amino acid sequence of SEQ ID NO:46; and a CDR3 comprising the amino acid sequence of SEQ ID NO:64; or
e) the VHH1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:11; a CDR2 comprising the amino acid sequence of SEQ ID NO:12; and a CDR3 comprising the amino acid sequence of SEQ ID NO:13; the VHH2 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:22; a CDR2 comprising the amino acid sequence of SEQ ID NO:23; and a CDR3 comprising the amino acid sequence of SEQ ID NO:24; the VHH3 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:37; a CDR2 comprising the amino acid sequence of SEQ ID NO:38; and a CDR3 comprising the amino acid sequence of SEQ ID NO:39 or 62; and the VHH4 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:48; a CDR2 comprising the amino acid sequence of SEQ ID NO:49; and a CDR3 comprising the amino acid sequence of SEQ ID NO:50 or 65; or
f) the VHH1 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:11; a CDR2 comprising the amino acid sequence of SEQ ID NO:12; and a CDR3 comprising the amino acid sequence of SEQ ID NO:13; the VHH2 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:22; a CDR2 comprising the amino acid sequence of SEQ ID NO:23; and a CDR3 comprising the amino acid sequence of SEQ ID NO:24; the VHH3 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:37; a CDR2 comprising the amino acid sequence of SEQ ID NO:38; and a CDR3 comprising the amino acid sequence of SEQ ID NO:62; and the VHH4 comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:48; a CDR2 comprising the amino acid sequence of SEQ ID NO:49; and a CDR3 comprising the amino acid sequence of SEQ ID NO:65.

### Claim at position 2

2-7. (canceled)

### Claim 8 (depends on 1)

The bispecific polypeptide of claim 1, wherein the VHH1 of the first co-binder comprises the amino acid sequence of SEQ ID NO:3 or 4, or amino acid residues 2-118 of SEQ ID NO:3 or 4, and the VHH2 of the first co-binder comprises the amino acid sequence of SEQ ID NO:14 or 15, or amino acid residues 2-119 of SEQ ID NO:14 or 15.

### Claim 9 (depends on 1)

The bispecific polypeptide of claim 1, wherein the VHH1 of the first co-binder comprises the amino acid sequence of SEQ ID NO:4, or amino acid residues 2-118 of SEQ ID NO:4, and the VHH2 of the first co-binder comprises the amino acid sequence of SEQ ID NO:15, or amino acid residues 2-119 of SEQ ID NO:15.

### Claim at position 5

10-13. (canceled)

### Claim 14 (depends on 1)

The bispecific polypeptide of claim 1, wherein the VHH3 of the second co-binder comprises the amino acid sequence of SEQ ID NO:29 or 30, or amino acid residues 2-115 of SEQ ID NO:29 or 30; and the VHH4 of the second co-binder comprises the amino acid sequence of SEQ ID NO:40 or 41, or amino acid residues 2-127 of SEQ ID NO:40 or 41.

### Claim 15 (depends on 1)

The bispecific polypeptide of claim 1, wherein the VHH3 of the second co-binder comprises the amino acid sequence of SEQ ID NO:30, or amino acid residues 2-115 of SEQ ID NO:30; and the VHH4 of the second co-binder comprises the amino acid sequence of SEQ ID NO:41, or amino acid residues 2-127 of SEQ ID NO:41.

### Claim 16 (depends on 1)

The bispecific polypeptide of claim 1, wherein the VHH1 of the first co-binder comprises the amino acid sequence of SEQ ID NO:4, or amino acid residues 2-118 of SEQ ID NO:4, wherein the VHH2 of the first co-binder comprises the amino acid sequence of SEQ ID NO:15, or amino acid residues 2-119 of SEQ ID NO:15, wherein the VHH3 of the second co-binder comprises the amino acid sequence of SEQ ID NO:30, or amino acid residues 2-115 of SEQ ID NO:30; and wherein the VHH4 of the second co-binder comprises the amino acid sequence of SEQ ID NO:41, or amino acid residues 2-127 of SEQ ID NO:41.

### Claim 17 (depends on 16)

The bispecific polypeptide of claim 16, wherein the VHH1 of the first co-binder is connected to the VHH2 of the first co-binder by a first linker; wherein the VHH3 of the second co-binder is connected to the VHH4 of the second co-binder by a second linker, wherein the first co-binder has the structure: [VHH1]-first linker-[VHH2]; and wherein the second co-binder has the structure: [VHH3]-second linker-[VHH4].

### Claim at position 10

18-19. (canceled)

### Claim 20 (depends on 1)

The bispecific polypeptide of claim 1, wherein the first co-binder comprises the amino acid sequence of SEQ ID NO:25 or 26 or the amino acid residues 2-275 of SEQ ID NO:25 or 26.

### Claim 21 (depends on 1)

The bispecific polypeptide of claim 1, wherein the first co-binder comprises the amino acid sequence of SEQ ID NO:26 or the amino acid residues 2-275 of SEQ ID NO:26.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The bispecific polypeptide of claim 1, wherein the second co-binder comprises the amino acid sequence of SEQ ID NO:51 or 52, or the amino acid residues 2-280 of SEQ ID NO:51 or 52.

### Claim 24 (depends on 1)

The bispecific polypeptide of claim 1, wherein the second co-binder comprises the amino acid sequence of SEQ ID NO:52, or the amino acid residues 2-280 of SEQ ID NO:52.

### Claim 25 (depends on 1)

The bispecific polypeptide of claim 1, wherein the bispecific polypeptide comprises a third linker, and wherein the bispecific polypeptide has a structure of [first co-binder]-Fc region-third linker-[second co-binder].

### Claim at position 17

26-32. (canceled)

### Claim 33 (depends on 25)

The bispecific polypeptide of claim 25, wherein the first linker comprises the amino acid sequence of SEQ ID NO:66, wherein the second linker comprises the amino acid sequence of SEQ ID NO:67, and wherein the third linker comprises the amino acid sequence of SEQ ID NO:68.

### Claim at position 19

34-35. (canceled)

### Claim 36 (depends on 25)

The bispecific polypeptide of claim 25, wherein the Fc region comprises a human IgG1 Fc region.

### Claim at position 21

37-41. (canceled)

### Claim 42 (depends on 36)

The bispecific polypeptide of claim 36, wherein the Fc region comprises the amino acid sequence of SEQ ID NO:59 or amino acid residues 1-231 of SEQ ID NO:59.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

The bispecific polypeptide of claim 1, wherein the bispecific polypeptide comprises the amino acid sequence of any one of SEQ ID NOs:55-58 or amino acid residues 1-797 of SEQ ID NO:56 or 58.

### Claim 45

A bispecific polypeptide that binds IL31 and IL13 comprising the amino acid sequence of SEQ ID NO:55.

### Claim at position 26

46-47. (canceled)

### Claim 48 (depends on 1)

The bispecific polypeptide of claim 1, wherein the bispecific polypeptide binds to human IL13 at a kD of less than or equal to 1×10−9 M, as measured by surface plasmon resonance; and wherein the bispecific polypeptide binds to human IL31 at a kD of less than or equal to 1×10−9M, as measured by surface plasmon resonance.

### Claim 49

(canceled)

### Claim 50 (depends on 45)

A multimeric polypeptide, comprising two of the bispecific polypeptides of claim 45.

### Claim at position 30

51-52. (canceled)

### Claim 53 (depends on 45)

A pharmaceutical composition comprising the bispecific polypeptide of claim 45 and a pharmaceutically acceptable carrier.

### Claim 54 (depends on 1)

An isolated nucleic acid that encodes the bispecific polypeptide of claim 1.

### Claim at position 33

55-57. (canceled)

### Claim 58 (depends on 54)

A method of producing a bispecific polypeptide that binds IL31 and IL13, comprising transfecting the isolated nucleic acid of claim 54 into a host cell under conditions suitable for expression of the bispecific polypeptide.

### Claim 59

(canceled)

### Claim 60 (depends on 45)

A method for treating a subject having an IL13-associated condition and/or an IL31-associated condition comprising administering to the subject a therapeutically effective amount of the bispecific polypeptide of claim 45.

### Claim at position 37

61-72. (canceled)

### Claim 73

A bispecific polypeptide that binds IL31 and IL13 comprising a first co-binder that specifically binds IL31 and a second co-binder that specifically binds IL13, wherein the first co-binder comprises the amino acid sequence of SEQ ID NO:26 or the amino acid residues 2-275 of SEQ ID NO:26, and wherein the second co-binder comprises the amino acid sequence of SEQ ID NO:52, or the amino acid residues 2-280 of SEQ ID NO:52.

### Claim 74 (depends on 73)

The bispecific polypeptide of claim 73, wherein the bispecific polypeptide comprises a third linker, and wherein the bispecific polypeptide has a structure of [first co-binder]-Fc region-third linker-[second co-binder].

### Claim 75 (depends on 74)

The bispecific polypeptide of claim 74, wherein the Fc region comprises a human IgG1 Fc region.

### Claim 76 (depends on 73)

A pharmaceutical composition comprising the bispecific polypeptide of claim 73 and a pharmaceutically acceptable carrier.

### Claim 77 (depends on 50)

A pharmaceutical composition comprising the multimeric polypeptide of claim 50 and a pharmaceutically acceptable carrier.

### Claim 78 (depends on 73)

A method for treating a subject having an IL13-associated condition and/or an IL31-associated condition comprising administering to the subject a therapeutically effective amount of the bispecific polypeptide of claim 73.

### Claim 79 (depends on 50)

A method for treating a subject having an IL13-associated condition and/or an IL31-associated condition comprising administering to the subject a therapeutically effective amount of the multimeric polypeptide of claim 50.
